Abstract:Lack of engraftment, graft-versus-host disease (GVHD) and tumor relapse are major issues that affect clinical outcome after allogeneic bone marrow transplantation (allo-BMT). Donor T cells in the graft present a dilemma in allo-BMT due to both the beneficial and deleterious clinical effects they can exert. Therefore, modulation of donor T cell function may represent a potential therapeutic approach in allo-BMT. In murine allo-BMT models, It has been demonstrated that donor T cell-derived IFN-gamma is required for optimal graft-versus-tumor (GVT) responses but it also plays complex roles by exhibiting both protective and pathogenic effects in GVHD development. We therefore investigated the role of IFN-gamma responsiveness by the donor T cells in allo-BMT through the use of IFN-gamma receptor deficient (IfnR−/−; RKO) mice. In these experiments, recipient BALB/c (H2d) mice received lethal total body irradiation. Irradiation was followed by the infusion of graded doses of T cell-depleted (TCD) allogeneic bone marrow cells (5 or 15 × 106) intravenously from major histocompatibility complex (MHC)-disparate wild type (WT) C57BL/6 (H2b, IfnR+/+) mice, with or without 0.5 × 106 T cells (or 3 × 106 splenocytes as a source of allogeneic T cells) from either WT (H2b, IfnR+/+) or RKO mice. Compared with transplantation of WT TCD-BMCs with T cells from a WT donor, we found that transplantation of WT TCD-BMCs with RKO T cells resulted in marked and significant increases in myeloid engraftment as determined by CFU-GM, peripheral neutrophil and platelet counts during the early phase of allo-BMT. Consistently, a significant increase serum G-CSF was also found on day 7 after allo-BMT with this group. This enhanced myeloid engraftment by RKO T cells occurred only in murine allo-BMT but not syngeneic BMT models, indicating it is a property of alloreactivity. Interestingly, no significant differences in donor T cell engraftment, nor in the percentage of Treg, Th17, CD4+ or CD8+ T cell subsets and IFN-gamma+ T cells, were observed in spleen. However, on day 7 after allo-BMT, significantly fewer donor T cells were observed in the gut in the recipient of RKO T cells compared to recipients of WT T cells. This reduction of donor T cells in gut was associated with a significant decrease in early acute GVHD lethality. This novel finding suggests transplantation of T cells lacking IFN-gamma receptors resulted in less donor T cell homing to the gut during the early phase of allo-BMT. We next addressed the ability of donor RKO T cells to provide GVT responses. A20 tumor-bearing BALB/c (H2d) mice were transplanted with WT C57BL/6 TCD-BMC. Compared with transplantation of 1 × 106 WT T cells with WT TCD-BMC, co-transplantation of 1 × 106 RKO T cells with WT TCD-BMC resulted in less GVHD-related mortality with greater anti-tumor effects. Taken together, these observations suggest that targeting IFN-gamma receptor signaling on donor T cells may help to improve the efficacy of allo-BMT by promoting donor myeloid engraftment and decreasing early acute GVHD lethality with greater GVT potential due to altered lymphocyte homing.

Donor NK Cells and IL-15 Promoted Engraftment in Nonmyeloablative Allogeneic Bone Marrow Transplantation.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Experimental Study on IL-2-and IL-15 Appficafion in Allogeneic Hematopoiefic Stem Cell Transplantation

The Role Of Donor Memory-Like Nk Cell Infusion In Allogeneic Hematopoietic Stem Cell Transplantation

[Experimental Study of Donor Natural Killer Cells Reducing Graft-Versus-host Disease and Enhancing Engraftment].

[Influence of Donor Treg Cells on GVHD and GVL Effects after Allogeneic Bone Marrow Transplantation in Mice].

Effectiveness of donor natural killer cell infusion in haplo-identical hematopoietic stem cell transplantation

Donor T Cells Lacking IFN-Gamma Receptor Expression Enhance Donor Myeloid Engraftment and Decrease Early Acute Graft-Versus-Host Disease Mortality Following Allogeneic Bone Marrow Transplantation

Suppression of Graft-Versus-host Disease and Amplification of Graft-Versus-tumor Effects by Activated Natural Killer Cells after Allogeneic Bone Marrow Transplantation.

Alloreactive Natural Killer Cells Reduce Graft-Versus-Host Disease And Enhance Engraftment In Mice Bone Marrow Transplantation Model.

[Role of Alloreactive Natural Killer Cell in Mouse MHC Haploidentical Bone Marrow Transplantation].

IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation

Role of NK Cells in Mouse Allogeneic Bone Marrow Transplantation

[Effect of Activated Donor-Type NK Cells on Allogeneic Bone Marrow Transplantation in Mice].

Mouse Host Unlicensed NK Cells Promote Donor Allogeneic Bone Marrow Engraftment.

[Effect of Natural Killer Cell on Hematopoiesis and Immunity Recovery in Mouse Allogeneic Bone Marrow Transplantation].

Donor Double‐negative Treg Promote Allogeneic Mixed Chimerism and Tolerance

Effect of NK Cells on GVHD in H-2 Haploidentical Bone Marrow Transplantation in Mice

Donor Γδt Cells Promote Graft-Versus-leukemia Effect and Ameliorate Acute Graft-Versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

Association of Natural Killer Cells in Allografts with Transplant Outcomes in Patients Receiving G-Csf-Mobilized Pbsc Grafts and G-Csf-Primed Bm Grafts from Hla-Haploidentical Donors

Characterization of NK1.1+ CD8 T Cells in Allogeneic Hematopoietic Cell Transplantation Recipients